Practice Management
Conference Coverage
Cancer drug prices higher in U.S. than Europe; don’t correlate with clinical benefit
BARCELONA – Cancer drug prices are significantly higher in the United states than in Europe, and they don’t correlate with clinical benefit in...
From the Journals
Automatic reenrollment helps keep people insured
Losing the automatic enrollment option was associated with a 30% drop in enrollment.
Feature
Business case for interoperability remains elusive
Dr. Robert Bart sees efforts to bring ownership of health data to the individual and a clearer definition of health IT standards as important...
From the Journals
Most practices not screening for five social needs
The majority of the overall screening activity was driven by interpersonal violence screenings.
Feature
States pass record number of laws to reel in drug prices
Measures include authorizing imported prescription drugs, screening for excessive price increases by drug companies, and establishing oversight...
Feature
How do social determinants of health play out in physician practice?
Documenting and coding social factors in the patient’s health care needs doesn’t necessarily change reimbursement for their care.
From the Journals
Cancer patients increasingly being discharged to subacute rehabilitation facilities
Although the intent may be for patients to become well enough to tolerate immunotherapy, about one-third end up receiving additional cancer-...
Feature
Insurers to pay record number of rebates to patients
Insurers will pay $1.3 billion in medical loss ratio rebates to patients in 2019 based on collected premiums.
From the Journals
Many experimental drugs veer off course when targeting cancer
Ten anticancer drugs in development target proteins that are not essential for the survival or growth of cancer cells, investigators caution.
Feature
CVS-Aetna merger approval gets poor review from physicians
Physician groups are raising concerns over the merger of pharmacy chain CVS Health and health insurer Aetna.
Conference Coverage
Out-of-pocket cost of oral TKIs linked to poor lung cancer survival
ALEXANDRIA, VA. – If confirmed in a nationally representative study, findings could have implications for health policy and oncology practice.